Publication: Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes
1
Issued Date
2021-01-01
Resource Type
ISSN
13652516
13518216
13518216
Other identifier(s)
2-s2.0-85102090684
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Haemophilia. Vol.27, No.1 (2021), 69-80
Suggested Citation
Ampaiwan Chuansumrit, Nongnuch Sirachainan, Rungrote Natesirinilkul, Kwannut Srikala, Narongrit Masaya-anon, Ajchariya Sarovath, Atthaporn Boongird, Bunchoo Pongtanakul, Chalermpong Chatdokmaiprai, Chane Cheod-amphai, Chusak Kijkunasathian, Jakrapan Jirasiritham, Jariya Pree-siri, Jumroon Tungkeeratichai, Monratta Panuwannakorn, Nantana Sri-Udomporn, Natsaruth Songthawee, Pantep Angchaisuksiri, Pakawan Wongwerawattanakoon, Praguywan Kadegasem, Pimlak Charoenkwan, Pimpun Kitpoka, Siranee Wongruangsri, Suphaneewan Jaovisidha, Surapong Lertthammakiat, Tanit Virankabutra, Werasak Sasanakul, Yujinda Lektrakul Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes. Haemophilia. Vol.27, No.1 (2021), 69-80. doi:10.1111/hae.14194 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78806
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes
Author(s)
Ampaiwan Chuansumrit
Nongnuch Sirachainan
Rungrote Natesirinilkul
Kwannut Srikala
Narongrit Masaya-anon
Ajchariya Sarovath
Atthaporn Boongird
Bunchoo Pongtanakul
Chalermpong Chatdokmaiprai
Chane Cheod-amphai
Chusak Kijkunasathian
Jakrapan Jirasiritham
Jariya Pree-siri
Jumroon Tungkeeratichai
Monratta Panuwannakorn
Nantana Sri-Udomporn
Natsaruth Songthawee
Pantep Angchaisuksiri
Pakawan Wongwerawattanakoon
Praguywan Kadegasem
Pimlak Charoenkwan
Pimpun Kitpoka
Siranee Wongruangsri
Suphaneewan Jaovisidha
Surapong Lertthammakiat
Tanit Virankabutra
Werasak Sasanakul
Yujinda Lektrakul
Nongnuch Sirachainan
Rungrote Natesirinilkul
Kwannut Srikala
Narongrit Masaya-anon
Ajchariya Sarovath
Atthaporn Boongird
Bunchoo Pongtanakul
Chalermpong Chatdokmaiprai
Chane Cheod-amphai
Chusak Kijkunasathian
Jakrapan Jirasiritham
Jariya Pree-siri
Jumroon Tungkeeratichai
Monratta Panuwannakorn
Nantana Sri-Udomporn
Natsaruth Songthawee
Pantep Angchaisuksiri
Pakawan Wongwerawattanakoon
Praguywan Kadegasem
Pimlak Charoenkwan
Pimpun Kitpoka
Siranee Wongruangsri
Suphaneewan Jaovisidha
Surapong Lertthammakiat
Tanit Virankabutra
Werasak Sasanakul
Yujinda Lektrakul
Abstract
Objective: This study aimed to explore real-world evidence on health resource use (HRU) spending on patients with haemophilia and inhibitor. Materials and methods: Medical records from 1990 to 2019 of patients with haemophilia and inhibitor from three comprehensive haemophilia treatment centres were retrospectively retrieved. Results: In all, 31 patients with haemophilia (A = 30, B = 1) and inhibitor ≥5 BU were included. The mean initial inhibitor of 95.4 BU was detected at the mean age of 6.7 years. The mean number of annual hospitalisations was 3.9. A total of 795 bleeding episodes (major =125, minor =670) were evaluated. The treatment included bypassing agents or plasma exchange before administering high-dose factor VIII concentrate and intervention or surgery. Six patients succumbed to bleeding at the mean age of 17.2 years. Nineteen surviving patients experienced multiple morbidity except six patients with successful and partially successful immune tolerance induction (ITI). The mean (SD) annual total medical consumption for episodic treatment and successful ITI per patient with haemophilia A were 30,804 (81,332) USD and 55,531 (100,566) USD, respectively. Only episodic treatment was paid by the government budget for limited amounts of bypassing agents. Conclusion: Management for patients with haemophilia and inhibitor exhibiting severe bleeding is challenging for medical personnel in countries having limited resources over decades. The real-world data will be used to negotiate with the government to increase budget for adequate bypassing agents or nonreplacement therapy and to include ITI in the national haemophilia treatment.